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Abstract
Background: Convulsive status epilepticus (CSE) is the most common life-threatening neurological emergency in
childhood. These children are also at risk of significant morbidity, with acute and chronic impact on the family and
the health and social care systems. The current recommended first-choice, second-line treatment in children aged
6 months and above is intravenous phenytoin (fosphenytoin in the USA), although there is a lack of evidence for its
use and it is associated with significant side effects. Emerging evidence suggests that intravenous levetiracetam
may be effective as a second-line agent for CSE, and fewer adverse effects have been described. This trial therefore
aims to determine whether intravenous phenytoin or levetiracetam is more effective, and safer, in treating childhood CSE.
Methods/design: This is a phase IV, multi-centre, parallel group, randomised controlled, open-label trial. Following
treatment for CSE with first-line treatment, children with ongoing seizures are randomised to receive either phenytoin
(20 mg/kg, maximum 2 g) or levetiracetam (40 mg/kg, maximum 2.5 g) intravenously. The primary outcome measure is
the cessation of all visible signs of CSE as determined by the treating clinician. Secondary outcome measures include the
need for further anti-seizure medications or rapid sequence induction for ongoing CSE, admission to critical care areas,
and serious adverse reactions. Patients are recruited without prior consent, with deferred consent sought at an
appropriate time for the family. The primary analysis will be by intention-to-treat. The primary outcome is a time to
event outcome and a sample size of 140 participants in each group will have 80% power to detect an increase in CSE
cessation rates from 60% to 75%. Our total sample size of 308 randomised and treated participants will allow for 10%
loss to follow-up.
Discussion: This clinical trial will determine whether phenytoin or levetiracetam is more effective as an intravenous
second-line agent for CSE, and provide evidence for management recommendations. In addition, this trial will also
provide data on which of these therapies is safer in this setting.
Trial registration: ISRCTN identifier, ISRCTN22567894. Registered on 27 August 2015
EudraCT identifier, 2014-002188-13. Registered on 21 May 2014
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Background
Convulsive status epilepticus (CSE) is the most common
life-threatening neurological emergency in children, with
an incidence of 20 per 100,000 children per year [1, 2].
It is the second most common reason for unplanned ad-
mission to paediatric intensive care units (PICUs) in the
UK, accounting for 5.6% of all PICU admissions [3].
These children are also at increased risk of irreversible
morbidity including chronic drug-resistant epilepsy, neu-
rodisability, and learning difficulties, which result in
major long-term demands on acute and chronic health
and social care resources [4].
The current UK emergency care pathway for the man-
agement of childhood CSE is the step-wise algorithm ad-
vocated in advanced paediatric life support (APLS) [5].
First-line treatment is two doses of a benzodiazepine
given 10 min apart; if the child continues to fit 10 min after
the second dose of benzodiazepine, a second-line anticon-
vulsant is administered. APLS recommends phenytoin as
the first-choice second-line anticonvulsant; if the child is
allergic to phenytoin, has previously not responded to it, or
has experienced a serious adverse event (SAE), phenobar-
bital is recommended. Failure to stop CSE necessitates
rapid sequence induction (RSI), intubation, and admission
to the PICU, with consequent potential for iatrogenic con-
sequences including pneumonia, hospital-acquired infec-
tions, and prolonged admission.
There is an absence of randomised evidence to sup-
port the use of phenytoin as the second-line anticonvul-
sant despite its use as a standard intravenous (IV)
anticonvulsant for the treatment of CSE since the 1940s.
A retrospective case note review in which 87% (331/381)
children administered a second-line anticonvulsant re-
ceived phenytoin reported seizure cessation in 190 cases
(50%) [6]. There is considerably more literature on phe-
nytoin’s potential adverse effects, including potentially
fatal cardiac arrhythmias and Stevens-Johnson syndrome
(Table 1) [7–9]. The risk of a cardiac arrhythmia is re-
lated to the rate of infusion and phenytoin is therefore
infused over at least 20 min.
Levetiracetam is a broad-spectrum anticonvulsant
which effectively treats focal and generalised tonic-clonic
and myoclonic seizures. A growing body of evidence,
predominantly but not exclusively anecdotal, suggests
that IV levetiracetam is safe and effective in the treat-
ment of acute repetitive seizures and both convulsive
and non-convulsive status epilepticus, with reported
seizure cessation rates between 76 and 100% [10–18].
Both levetiracetam and lorazepam seem to be equally ef-
fective in terminating CSE (relative risk 0.97, 95% confi-
dence interval 0.44 to 2.13) [19]. A systematic review
published in 2012 indicated that efficacy ranged from 44
to 94% with reported higher rates in retrospective stud-
ies [20]. Reported IV levetiracetam doses range from 20
to 60 mg/kg with infrequent and mild adverse effects
even at the upper extreme of the dose range [21]. These
include dizziness, somnolence, headache, and transient
agitation, but there have been no reports of arrhythmias,
hypotension, tissue extravasation reactions, Stevens-
Johnson syndrome, or hepatotoxicity (Table 1) [21, 22].
Levetiracetam can be infused over 5–7 min, which sug-
gests that, theoretically, CSE may be terminated more
rapidly than with phenytoin. Consequently, a reasonable
hypothesis is that levetiracetam may be more effective
and safer than intravenous phenytoin in terminating
CSE [10, 23, 24].
CSE management has been identified as a key priority
area for research by a number of sources including the
national paediatric emergency medicine research net-
work (Paediatric Emergency Research in the United
Kingdom & Ireland; PERUKI) [25] in their inaugural pri-
oritisation exercise [26], and the National Institute for
Health and Care Excellence (NICE) in their update of
their national epilepsy guideline published in January
2012 [27]. A high-quality randomised controlled trial
(RCT) is therefore essential to determine whether
Table 1 Comparison of phenytoin and levetiracetam
Phenytoin Levetiracetam
Easy to administera ☒ ☑
Rapid onset of actiona ☑
Intermediate to long actiona ☑ ☑
Broad spectruma ☒ ☑
Minimal morbiditya ☒ ☑
Useful as maintenance
AEDa
☑ ☑
IV solution compatibilitya ☒ ☑
Rate of infusion 20 min (minimum) 5 min
(minimum)
Effectiveness in CSE (seizure
termination rate)
50–60% 75–100%
Evidence base
Cost
Interactions with other
drugs
Adverse effects
Potentially fatal Cardiac arrhythmia
Cardiac asystole
Stevens-Johnson
syndrome
Non-fatal Hypotension
Hepatotoxicity
Phlebitis
Severe extravasation injury
(‘purple glove syndrome’)
Dizziness
Somnolence
Headache
Agitation
IV site
irritation
aCharacteristics of ideal intravenous AEDs as outlined by Wheless and
Treiman [41]
AED anti-epileptic drug, CSE convulsive status epilepticus, IV intravenous
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phenytoin or levetiracetam is the ideal drug in CSE, as
highlighted in the recent systematic review [20].
The EcLiPSE study (Emergency treatment with Leveti-
racetam or Phenytoin in Status Epilepticus in children)
is a phase IV, multi-centre, parallel group, randomised
controlled, open-label trial comparing IV levetiracetam
with IV phenytoin. The study objectives are to deter-
mine which treatment is: 1) more effective as a second-
line anticonvulsant for the management of childhood
CSE; 2) associated with fewer adverse effects.
Methods
The protocol for this study has been written in accordance
with the Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) checklist (Additional file 1).
Study setting
Thirty Emergency Departments (ED) throughout all re-
gions of the UK are participating, selected from the
membership of PERUKI, a collaborative paediatric emer-
gency medicine research network [25]. Participating sites
may be tertiary or district general hospitals with EDs
that treat either children alone, or children and adults. A
full list of participating centres is available on the EcLiPSE
website (http://www.eclipse-study.org.uk/). Centres are se-
lected based on factors including site research infrastruc-
ture, number of likely recruits, and proposed training
strategy.
Study population
Inclusion criteria
Children aged 6 months to <18 years who present with
generalised tonic-clonic, generalised clonic, or focal
clonic CSE that requires second-line treatment, provided
that first-line treatment has been administered according
to APLS guidelines [5] or the child’s personalised rescue
care plan. If patients are given more than two doses of
benzodiazepines (for example, in the community and
then the ED), or fewer than two doses (for example, due
to previous benzodiazepine sensitivity), or where the
personalised care plan includes rectal paraldehyde as
first-line treatment, then they are still eligible. Children
receiving oral phenytoin or levetiracetam as mainten-
ance therapy are eligible.
Exclusion criteria
Children are excluded if they: 1) present with absence,
myoclonic, or non-convulsive status epilepticus, or in-
fantile spasms; 2) are known or suspected to be preg-
nant; 3) have a known contraindication or allergy to
levetiracetam or phenytoin; 4) have known established
renal failure; 5) have been given a second-line antiepilep-
tic drug during this episode of CSE prior to eligibility
assessment; or 6) are known to have previously been
treated in the EcLiPSE study.
Outcome measures
The primary outcome is time from randomisation to
cessation of all visible signs of CSE activity. The second-
ary outcomes are: 1) need for further anticonvulsants to
manage seizures after randomised treatment; 2) need for
RSI due to ongoing CSE; 3) need for admission to a
PICU or high-dependency unit (HDU); and 5) serious
adverse reactions (SARs) including death, airway compli-
cations, cardiovascular instability, extravasation injury,
and extreme agitation.
Screening, randomisation, recruitment, and consent
The overall study flowchart is presented in Fig. 1.
Screening
Screening commences once a child arrives in the ED
and has received first-line treatment for CSE. A unique
participant screening form is used which includes an eli-
gibility assessment and reasons for non-randomisation
where appropriate.
Randomisation and recruitment
Eligible children are randomised following completion of
first-line therapy if the CSE is ongoing, enabling prepar-
ation and administration of the allocated treatment in a
timeframe consistent with APLS guidance [5]. If the CSE
terminates prior to administration of the allocated treat-
ment then the patient may still be given that treatment
if the CSE restarts while they remain in the ED. Rando-
mised participants who do not receive a second-line
treatment in the ED will not be included in the primary
outcome analysis.
Screening data from randomised participants who do
not receive a second-line treatment in the ED will be
collected and analysed in conjunction with randomised
and treated participants.
Participants are randomised to levetiracetam or pheny-
toin in a ratio of 1:1 (Fig. 2), and the randomisation code
list is generated by an independent statistician. Random-
isation packs are sequentially numbered opaque tamper-
proof envelopes, to be opened in ascending order.
Checks are performed periodically to ensure the correct
number of randomisation packs is present, that they are
intact, and that the sequential numbering system is
maintained. The envelopes contain the first case report
form (CRF) which is completed in the ED during the
CSE episode. Data collected include time of drug admin-
istration, CSE cessation, additional therapy required, ad-
verse events, and admission location.
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Follow-up
There are three time-periods for data collection in the
EcLiPSE study (Figs. 1, 2, and 3). The first is in the ED
during the acute CSE treatment phase. The second is
the 24 h after allocated treatment, wherein data collected
include further seizures, concomitant anticonvulsants
that may have been required to treat other acute seizures,
and adverse events. Finally, safety follow-up is undertaken
14 days after administration of the randomised treatment
by review of hospital notes and a single-sheet, four-
question questionnaire completed by the child’s parents.
This includes information on whether there have been
further admissions or organ failure.
Blood samples
Samples are taken 1–2 h after completion of the rando-
mised treatment to measure drug levels, a common
practice when giving phenytoin [28]. Levetiracetam
levels are measured in an accredited central laboratory,
to which samples are not transferred until study consent
has been obtained. Measurement of phenytoin levels is
undertaken in the treating hospital.
Trial treatments
EcLiPSE is an open-label trial using investigational medi-
cinal products (IMPs) with marketing authorisation in
the UK. These only become IMPs when the packaging is
opened in the setting of this study. IMP provision is the
responsibility of each site in accordance with standard
clinical practice, and they are stored in line with local re-
quirements for general medicine supplies.
A single dose of the randomly allocated treatment is
administered by IV infusion. The levetiracetam dose is
40 mg/kg (maximum 2500 mg) over 5 min, diluted to a
Fig. 1 Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children (EcLiPSE) study flowchart. CSE convulsive status epilepticus
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maximum of 50 mg/ml with 0.9% sodium chloride. The
phenytoin dose is 20 mg/kg (maximum dose 2000 mg)
at a rate not exceeding 1 mg/kg/min (or longer than
20 min for doses of >1 g), diluted with 0.9% sodium
chloride to a maximum concentration of 10 mg/ml.
The allocated treatment is prepared and administered in
accordance with standard clinical care with independent
checking performed by two trained personnel. Trial-
specific labelling is not required; rather, an approved
“intravenous additive label” is used. If the randomised treat-
ment is discontinued prior to administration of the full
dose this is recorded. If CSE persists at the end of the IMP
infusion, further medical management is decided by the
local clinical team independent of the trial protocol (Fig. 2).
Consent study
EcLiPSE includes a mixed method study (consent study)
involving participants and trial recruiters to explore: 1)
Fig. 2 Schematic of Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children (EcLiPSE) study design.
1Administration of the first-line treatment may have occurred prior to arrival in the ED. 2If a patient is randomised but not treated with a second-line
anticonvulsant, follow-up would end at this point. APLS advanced paediatric life support, CRF case report form, ED Emergency Department
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how information about the trial and deferred consent is
exchanged during recruitment discussions; 2) views on
deferred consent and participant decision making; 3) the
impact of an un-blinded trial design; and 4) trial re-
cruiter training [29–31]. The objective of the consent
study is to identify potential barriers and solutions to re-
cruitment and consent. This will inform recruiter train-
ing both during EcLiPSE and also inform approaches to
recruitment and consent for future paediatric critical
care trials. The consent study involves the following.
Audio-recording of recruitment and consent discussions
between families and trial recruiters
EcLiPSE recruiters seek verbal permission to audio-record
recruitment consultations when they first approach fam-
ilies about EcLiPSE; if permission is declined the recruit-
ment consultation is not recorded. If there is more than
one trial discussion, then all are recorded. Audio-recording
occurs for the first 4 months of the trial at each site, or
until data saturation is achieved [32].
Questionnaires completed by participant representatives
after EcLiPSE consent discussions
EcLiPSE trial recruiters will invite all participants (in-
cluding those who decline deferred consent) to complete
an online or paper consent study questionnaire. If more
than one participant is involved in the consent discus-
sion, then all are invited to complete a questionnaire.
Telephone interviews with up to 25 parents of patients,
16- to 18-year-old patients with capacity, and one member
of each site team
EcLiPSE recruiters ask participants who agree or decline
consent if they wish to take part in a telephone inter-
view. If they agree, the consent study researcher contacts
them to arrange interviews within 1 month of the
Screening/ 
Randomisation
Follow-up
1-2 hours
after second-
line infusion 
completed
0-24 hours 
after start of 
second-line 
infusion 
14 days
after start of 
second-line 
infusion 
Informed consent (deferred) X
Assessment of eligibility criteria X
Weight (actual or estimate) X
Randomisation X
Study intervention X
Seizure activity X X
Assessment of adverse events X X
Study intervention 
compliance/accountability
X
Laboratory assessments: routine 
blood tests and levels of phenytoin
and levetiracetam 
X
Review of concomitant medications X
Physical examination: symptom-
directed*
(X)
Review of medical history X
Review of epilepsy history (age at 
onset of the epilepsy; epilepsy 
syndrome)
X
CRF Completion and data-query 
resolution
X X
CRF review and sign-off X X
14-day safety follow-up X
Fig. 3 Emergency treatment with Levetiracetam or Phenytoin in Status Epilepticus in children (EcLiPSE) study assessments. *This physical
examination should include a comment on any focal neurological signs. CRF case report form, X as indicated/appropriate
Lyttle et al. Trials  (2017) 18:283 Page 6 of 10
discussion. Interviews are likely to be conducted until
data saturation is reached [32]. One member of each site
team (Principal Investigator (PI) or research nurse) is
emailed by the consent study researcher asking them to
participate in a telephone interview within the first
4 months of site opening
Focus groups with EcLiPSE trial recruiters
At the end of the first year, the consent study researcher
will invite EcLiPSE staff in 6–10 sites to participate in a
focus group. Selection of sites for focus groups will be
based on recruitment rates (both high and low) and re-
cruitment issues identified in the analysis of audio-
recordings, questionnaires, and parent interviews
Table 2 summarises when each section of the consent
study is applicable to participants who have been rando-
mised and administered treatment. Participants can se-
lect which study elements they wish to take part in
during the consent process.
Statistical considerations
A separate and full statistical analysis plan will be devel-
oped prior to the final analysis of the trial and agreed by
the Trial Steering Committee (TSC).
Sample size estimation
Sample size estimation is based on published seizure
cessation rates for phenytoin (50–60%) [6] and levetirac-
etam (76–100%) [10–18, 22, 23]. A sample size of 140
participants in each group at a 0.05-level two-sided log-
rank test for equality of survival curves will have 80%
power to detect an increase in seizure cessation rates
from 60% to 75%, (a constant hazard ratio of 0.661). A
total of 308 randomised participants with deferred con-
sent and given randomised treatment will allow for 10%
loss to follow-up.
Statistical analysis plan
The primary analysis will be by ‘intention-to-treat’. A 5%
level of statistical significance will be used throughout
and all results will be presented with 95% confidence in-
tervals. The primary outcome is a time to event outcome
and will be analysed using the log-rank test and Kaplan-
Meier curves. Dichotomous outcomes will be analysed
using the chi-square test and presented with relative
risks. Adjusted analyses will be conducted using Cox
Proportional Hazards models or logistic regression, as
appropriate. Variables included in the models will be de-
termined from known prognostic factors. Adverse events
will be presented using descriptive statistics. Reasons for
missing data, and rates and reasons for not obtaining de-
ferred consent, will be monitored.
Consent study analysis
Consent study data analysis will be assisted using the
NVivo 8 qualitative data analysis package and SPSS soft-
ware for statistical analysis. Quantitative analysis will in-
volve descriptive statistics and the chi-square test for
trend. Qualitative data will be analysed thematically [33].
Data from study methods will be analysed separately and
then synthesised through the use of constant compara-
tive analysis [34, 35].
Safety monitoring
Safety is assessed by: 1) local research staff in the first
24 h after randomised treatment; 2) parent questionnaire
and hospital record review 14 days after treatment ad-
ministration; and 3) the Independent Data and Safety
Monitoring Committee (IDSMC). Reporting procedures
are determined by the nature of the event and investiga-
tors are provided with explanatory algorithms. All ad-
verse events (AEs) up to 24 h after allocated treatment
administration are recorded. Local investigators assign
the severity of AEs as mild, moderate, or severe in line
with definitions provided. A distinction is drawn be-
tween serious and severe AEs, and a severe AE need not
necessarily be a serious AE (SAE). An AE whose causal
relationship to the study drug is assessed as “possible”,
“probable”, or “definite” is an adverse reaction (AR). Al-
though ARs are not expected to occur more than 24 h
following randomised treatment, investigators will report
any AEs they feel are related, regardless of timing. Local
investigators assign causality, though if there is doubt
the Chief Investigator (CI) is notified.
Table 2 Consent study applicability
Consent sought from Location deferred
consent sought
Applicable sections of the consent study
Audio-recording Questionnaire Interview
Parent/legal representative On-site ✓ ✓ ✓
Bereaved parent/legal representative On-site ✓
Adult with capacity On-site ✓ ✓
Parent/legal representative Home ✓ ✓
Bereaved parent/legal representative Home ✓
Adult with capacity Home ✓
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On receipt of an SAE form, an assessment of expected-
ness is made by the CI. Serious unexpected events judged
to be possibly, probably, or almost certainly related to
the IMP are reported as suspected unexpected SARs
(SUSARs). SARs, SAEs, and SUSARs are reported
within 24 h of the local site becoming aware of the
event, with additional information within 5 days if it is
unresolved at the time of the initial report. Regulatory
agencies, research ethics committees (RECs), PIs, and
trial committees are notified of all SUSARs occurring
during the study. All AEs are followed-up until the
local PI deems there to be satisfactory resolution, the
event is chronic, or the participant is stable.
Incorrect administration or overdose of IMP (20% or
more above the recommended dose) is recorded. If this
results in an AE or SAE, reporting occurs as previously
described. Deaths during the reporting period are re-
corded as SAEs. The event or condition that caused or
contributed to death is recorded, though if it is unknown
it is recorded as “unexplained death”. If the cause of
death subsequently becomes known, this is recorded.
Trial monitoring
Quality control and quality assurance measures are in
place to ensure that all elements of the EcLiPSE study are
performed in compliance with applicable regulatory re-
quirements. These are undertaken by the Trial Manage-
ment Group (TMG), TSC, and IDSMC. An investigators’
meeting was hosted by the TMG, attended by PIs and site
research nurses, to provide an overview of the EcLiPSE
study. Site initiation visits are performed to deliver trial-
specific training to key clinical and research personnel,
which is subsequently cascaded to all relevant staff. Train-
ing and delegation logs are monitored for completeness,
and appropriate approvals must be in place prior to site
initiation. Screening, randomisation, and consent rates are
monitored, and data are checked for consistency and
missing or unusual values, with suspect data returned to
the site as data queries to ensure their reliability and
validity. The sponsor may also undertake site audits
throughout the trial.
Independent oversight is provided by the IDSMC and
independent members of the TSC. The IDSMC reviews
and assesses recruitment, interim analysis of safety and
effectiveness, trial conduct, and external data, and pro-
vides recommendations to the TSC concerning study
continuation. The Haybittle-Peto approach will be
employed for interim analyses with 99.9% confidence
intervals but decisions around trial continuation will
not be based on p values alone. The role of the TSC is
to provide overall supervision for the trial and provide
advice through its independent Chairperson. The ultim-
ate decision for the continuation of the trial lies with
the TSC.
Confidentiality
Participant medical information is confidential, and dis-
closure to third parties is prohibited with the exception
of name data which is transferred on informed consent/
assent forms. This transfer of identifiable data is dis-
closed in the participant information sheet.
Risk assessment
A risk assessment of potential patient, organisational,
and study hazards was performed prior to commence-
ment, involving all relevant stakeholders. The risks asso-
ciated with this study are deemed to be ‘no higher than
that of standard medical care’. This level of risk informs
the regulatory requirements, nature, and extent of the
monitoring, and the management processes used.
Regulatory approval
This trial falls within the remit of the UK Statutory
Instrument 2004 No 1031: Medicines for Human Use
(Clinical Trials) Regulations 2004 as amended. This trial
has been registered on EudraCT. The EudraCT reference
is 2014-002188-13.
Dissemination
The results of the EcLiPSE study will be published in
peer-reviewed journals and in a report published by the
National Institute for Health Research Health Technology
Assessment programme (NIHR HTA). The TMG forms
the basis of the Writing Committee which will follow the
Uniform Requirements for Manuscripts Submitted to Bio-
medical Journals (http://www.icmje.org/). Publications will
be distributed to participating centres, and throughout
relevant networks and bodies. Families that consent to re-
ceiving a copy of the findings will be sent a lay summary.
Findings will also be presented at relevant national and
international scientific (e.g. epilepsy, emergency medicine,
paediatric) conferences, and at meetings of relevant char-
ities, accompanied by press releases and dissemination via
other outlets.
Discussion
This study has a number of opportunities and challenges
which might affect recruitment. It is an example of
paediatric research in an emergency situation and conse-
quently has to involve either waived or deferred consent;
waived consent is ethically unacceptable in this setting
and research without prior consent will be a new con-
cept to many participating centres. However, deferred
consent was not an issue in a previous paediatric emer-
gency research study, the results of which led to a
change in national policy and practice in the manage-
ment of paediatric CSE [36]. Early input and advice was
obtained through patient and public involvement and all
site training includes a video scenario of a professional
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mock interview in which the study is discussed and de-
ferred consent is explained, processes designed to maxi-
mise recruitment into EcLiPSE. Early engagement with
PERUKI optimised success through collaboration with
clinicians and researchers in the development and deliv-
ery of the study, together with the selection of the most
appropriate sites in which to recruit patients.
Trial status
Recruitment to this study commenced in July 2015, and
to date 160 patients have been enrolled. Twenty-nine
sites are currently open to recruitment, with a plan to
recruit patients at 30 sites in total across the UK and
PERUKI network. Recruitment is scheduled to finish in
March 2018 and analysis be completed by December
2018.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOCX 60 kb)
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Ethics approval and consent to participate
Prospective informed consent cannot be sought in the EcLiPSE study as:
 CSE is a medical emergency with insufficient time to obtain
informed consent within the therapeutic window when following
current standard care
 Parents may not be present, and even when present they are likely to
be distressed by witnessing their child’s CSE, thereby compromising
their capacity to make an informed decision
Consent for participation is therefore by deferred consent (research without
prior consent) in line with applicable regulatory requirements, ethical
principles, and guidance on consent in critical care settings [37–40]. The use
of deferred consent in EcLiPSE was supported by parents who took part in
trial feasibility work [29].
Deferred consent (and assent where applicable) is sought for all randomised
participants, including those who do not receive the allocated treatment.
Legal representatives/parents/patients (hereafter called “participants”) are
asked to agree to the use of data and blood sample analysis that have been
collected, and to continue participation in the trial. Participants are
approached as soon as is reasonable after randomisation; ideally within 24 h,
but longer if the family is felt to need more time (for example, if the
patient’s condition remains critical or unstable). Research staff and clinical
staff work together to identify the most appropriate time point at which to
approach the family on a case-by-case basis [39].
The participants are provided with the appropriate Participant Information
and Consent/Assent forms, which includes general information (including
why deferred consent is used in critical care research, that participation in
the trial is voluntary, and that the participant may withdraw from the trial at
any time and for any reason) and study-specific information (including the
objectives, risks and inconveniences, and conditions under which the study
is conducted). All participants are asked to read and review the document
and are provided with the opportunity to ask questions, discuss the study,
and have time to consider the information prior to giving consent.
If consent is not sought prior to hospital discharge the family is contacted
by telephone within 5 working days of randomisation to inform them of
their child’s involvement and provide study details. They are posted further
study information and a covering letter which confirms that if no response is
received within 4 weeks the participant will automatically be included in the
trial. If consent is not obtained prior to transfer to another hospital (for example,
for PICU care) and the receiving hospital is an EcLiPSE site, then consent will be
sought at the receiving site wherever possible.
On the very rare occasion where the patient dies before consent is sought
the local clinical, bereavement, and research teams work together to
develop a bespoke approach for the family [39]. This includes identifying the
most appropriate clinician to notify parents of their child’s involvement in
research, and the most appropriate method and time of seeking consent.
Options include approaching the family before they leave hospital or
sending information by post 4 weeks later. Where postal communication is
used, unless the family notify the team that they wish to withdraw, data
already collected are used in the study. Specific materials and processes
have been developed to remain sensitive to families’ needs while still
offering the opportunity to participate in critical care research, an approach
which has been supported by parents [29].
The trial protocol, Participant Information sheets, Consent/Assent forms and
all other relevant trial documentation have been approved centrally by the
National Research Ethics Service (NRES) – Liverpool Central (REC reference:
15/NW/0090; approval date 3 March 2016) and all participating centres are
granted NHS permission prior to commencing recruitment.
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